Ongoing Clinical Trials
- Protocol I1F-MC-RHCR - A 24-Week Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis. November 2018
- Clinical Study Protocol M15-340 A Phase I, Open-Label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects with Polyarticular Course Juvenile Idiopathic Arthritis. November 2018
ACTIVELY RECRUITING OR ABOUT TO START:
- Clinical Study Protocol M14-431 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy. October 2018 – ongoing
- Clinical Study Protocol M14-433 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional Therapies but Have Not Failed Biologic Therapy. October 2018 - ongoing
- Protocol M19-130 Systemic Lupus Erythematosus: A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus. Actively recruiting
- M16-011. A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy. Actively recruiting
- Protocol I4V-MC-JAJA (RA-BRIDGE). Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis.
- M16-560. A phase 1b, Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Subjects with Moderate to Severe Rheumatoid Arthritis. actively recruiting
- M16-837. A Phase 2, Multicenter, Double-blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women with Polycystic Ovary Syndrome
- M16-824: Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women